AU2001277003A1 - Antisense inhibition of her-3 expression - Google Patents

Antisense inhibition of her-3 expression

Info

Publication number
AU2001277003A1
AU2001277003A1 AU2001277003A AU7700301A AU2001277003A1 AU 2001277003 A1 AU2001277003 A1 AU 2001277003A1 AU 2001277003 A AU2001277003 A AU 2001277003A AU 7700301 A AU7700301 A AU 7700301A AU 2001277003 A1 AU2001277003 A1 AU 2001277003A1
Authority
AU
Australia
Prior art keywords
expression
antisense inhibition
antisense
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277003A
Inventor
C. Frank Bennett
Lex M Cowsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2001277003A1 publication Critical patent/AU2001277003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001277003A 2000-07-31 2001-07-18 Antisense inhibition of her-3 expression Abandoned AU2001277003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09630706 2000-07-31
US09/630,706 US6277640B1 (en) 2000-07-31 2000-07-31 Antisense modulation of Her-3 expression
PCT/US2001/022751 WO2002010409A1 (en) 2000-07-31 2001-07-18 Antisense inhibition of her-3 expression

Publications (1)

Publication Number Publication Date
AU2001277003A1 true AU2001277003A1 (en) 2002-02-13

Family

ID=24528271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277003A Abandoned AU2001277003A1 (en) 2000-07-31 2001-07-18 Antisense inhibition of her-3 expression

Country Status (3)

Country Link
US (1) US6277640B1 (en)
AU (1) AU2001277003A1 (en)
WO (1) WO2002010409A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736587B2 (en) * 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
CA2446810A1 (en) * 2001-05-07 2002-11-14 Hybridon, Inc. Epidermal growth factor receptorantisense oligonucleotides
DE10131187C2 (en) * 2001-06-28 2003-06-18 Infineon Technologies Ag Exposure mask with repaired blind structure
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4762889B2 (en) * 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
WO2006001810A2 (en) * 2003-07-15 2006-01-05 California Institute Of Technology Improved inhibitor nucleic acids
CA2539181A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
JP2008514925A (en) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド Compositions and methods for detecting and treating tumors
WO2006127976A2 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Compositions and their uses directed to ptpru
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
NZ581201A (en) * 2007-05-11 2012-05-25 Enzon Pharmaceuticals Inc Rna antagonist compounds for the modulation of her3
AU2009316853A1 (en) 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
CA3077910A1 (en) * 2010-11-17 2012-05-24 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
KR102055331B1 (en) * 2011-04-21 2019-12-12 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of hepatitis b virus (hbv) expression
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
PE20201501A1 (en) 2018-01-12 2020-12-29 Bristol Myers Squibb Co ANTI-SENSE OLIGONUCLEOTIDES ACTING ON ALPHA-SINUCLEIN, AND USES OF THESE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (en) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Also Published As

Publication number Publication date
US6277640B1 (en) 2001-08-21
WO2002010409A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU2001229447A1 (en) Antisense modulation of smad7 expression
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2002339348A1 (en) Inhibition of STAT-1
AU2001277003A1 (en) Antisense inhibition of her-3 expression
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU1488501A (en) Methods of inhibiting metastasis
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU2001257220A1 (en) Antisense modulation of inhibitor of dna binding-1 expression
AU2001283443A1 (en) Antisense modulation of hpk/gck-like kinase expression
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU2002226064A1 (en) Antisense modulation of talin expression
AUPQ629000A0 (en) Inhibition of fungi
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2001296412A1 (en) Antisense modulation of mekk4 expression